专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150037367A1 Methods and Compositions Of Protein Antigens For The Diagnosis And Treatment of Herpes Simplex Viruses Type 1 and 2 审中-公开
标题翻译：蛋白质抗原的方法和组成用于诊断和治疗单纯疱疹病毒1型和2型
公开(公告)号：US20150037367A1
公开(公告)日：2015-02-05
申请号：US14130472
申请日：2012-06-29
申请人： David Huw Davies , Xiaowu Liang , Philip Felgner
发明人： David Huw Davies , Xiaowu Liang , Philip Felgner
IPC分类号： A61K39/245 , C12N7/00
CPC分类号： A61K39/245 , A61K39/12 , A61K2039/70 , C12N7/00 , C12N2710/16633 , C12N2710/16634 , G01N33/549 , G01N2333/035
摘要： Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
摘要翻译：从单纯疱疹病毒1型（HSV-1）和2型单纯疱疹病毒（HSV-2）中吸取各种抗原，以及它们在疫苗，治疗剂和各种诊断试验中的应用。在特别优选的方面，抗原是免疫显性的，并且相对于感染病原体的群体的血清具有定量和已知的相对反应性，和/或具有与疾病参数的已知关联。

2. 发明授权

US06232338B1 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors 失效
标题翻译： 4-巯基吡咯烷衍生物作为法呢基转移酶抑制剂
公开(公告)号：US06232338B1
公开(公告)日：2001-05-15
申请号：US09011135
申请日：1998-02-03
申请人： David Huw Davies , Francis Thomas Boyle , James Michael Wardleworth , Peter Wedderburn Kenny , Peter Beverley Scholes , Zbigniew Stanely Matusiak
发明人： David Huw Davies , Francis Thomas Boyle , James Michael Wardleworth , Peter Wedderburn Kenny , Peter Beverley Scholes , Zbigniew Stanely Matusiak
IPC分类号： A61K3140
CPC分类号： C07D401/12 , C07D207/12 , C07D409/12
摘要： Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.
摘要翻译：包含式（I）的ras法呢基酯化抑制剂的药物组合物，其中R1为例如本说明书中定义的其它值; R2是例如H和说明书中定义的其它值; R3是例如H或具有本说明书中定义的值的取代基; p为0-3，其中R3值可以相同或不同; L是例如-CO-NH 2的连接部分和如说明书中定义的进一步的值; A选自苯基; 萘基; 含有多达5个杂原子的5-10元单环或双环杂芳基环，其中杂原子独立地选自O，N和S; 或其-S-S-二聚体时，R 2 = H; 或其对映体，非对映异构体，药学上可接受的盐，前药或溶剂合物以及药学上可接受的稀释剂或载体。一个特别的用途是癌症治疗。

3. 发明授权

US09297803B2 Compositions and methods for immunodominant antigens 有权
标题翻译：免疫显性抗原的组合物和方法
公开(公告)号：US09297803B2
公开(公告)日：2016-03-29
申请号：US12447620
申请日：2007-11-01
申请人： Philip Felgner , David Huw Davies , Xiaowu Liang , Maria Laura Gennaro
发明人： Philip Felgner , David Huw Davies , Xiaowu Liang , Maria Laura Gennaro
IPC分类号： A61K39/12 , A61K39/02 , G01N33/569 , A61K39/015 , A61K39/04 , A61K39/118 , A61K39/245 , A61K39/285 , A61K39/385 , C07K14/005 , G01N33/566 , A61K39/00
CPC分类号： C12N15/1068 , A61K39/015 , A61K39/0208 , A61K39/0225 , A61K39/04 , A61K39/098 , A61K39/118 , A61K39/12 , A61K39/245 , A61K39/285 , A61K39/385 , A61K2039/60 , C07K14/005 , C12N2710/16621 , C12N2710/16622 , C12N2710/16634 , C12N2710/24122 , C12N2710/24134 , G01N33/566 , G01N33/56911 , G01N33/56916 , G01N33/56927 , G01N33/5695 , G01N33/56983 , G01N33/56994 , G01N33/6854 , G01N2333/35 , G01N2469/20 , Y02A50/401 , Y02A50/412
摘要： Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.
摘要翻译：考虑到的组合物，装置和方法包括来自选择的人类病原体的免疫显性抗原（伯克霍尔德氏菌属，布氏疏螺旋体，布鲁氏菌，衣原体衣原体，Coxiella burnetii，可用作疫苗，作为诊断标记物，以及用作治疗剂。在特别优选的方面，抗原相对于感染病原体的群体的血清具有定量和已知的相对反应性，并且具有与疾病参数的已知关联。

4. 发明授权

US5953311A Timing synchronization in a receiver employing orthogonal frequency division multiplexing 失效
标题翻译：采用正交频分复用的接收机中的定时同步
公开(公告)号：US5953311A
公开(公告)日：1999-09-14
申请号：US802328
申请日：1997-02-18
申请人： David Huw Davies , Jonathan Parker , Anthony Peter John Claydon
发明人： David Huw Davies , Jonathan Parker , Anthony Peter John Claydon
IPC分类号： H04L27/26 , H04J11/00 , H04J3/06
CPC分类号： H04L27/2676 , H04L27/2662 , H04L27/265
摘要： A method and apparatus are disclosed for determining the boundaries of guard intervals of data symbols being received in a coded orthogonal frequency division multiplexed signal. Temporal samples separated by an interval of an active interval of a data symbol are associated in pairs, and difference signals obtained. The dispersion of a first comparison block of difference signals is determined, and compared to the dispersion of a second comparison block of difference signals, the second comparison block being displaced from the first comparison block by n samples. An F ratio is calculated for the dispersions of the two blocks. F ratios are iterated in a succession of comparison blocks, and a signal representing the F ratios subjected to peak detection. The peaks represent the boundaries of the symbol's guard interval. This information is utilized in synchronizing an FFT window for subsequent signal reconstruction.
摘要翻译：公开了一种用于确定在经编码的正交频分复用信号中接收的数据符号的保护间隔的边界的方法和装置。通过数据符号的有效间隔的间隔分离的时间样本被成对地相关联，并且获得差分信号。确定差分信号的第一比较块的色散，并且与差分信号的第二比较块的色散进行比较，第二比较块从第一比较块移位n个样本。对于两个块的分散体计算F比率。 F比率在一系列比较块中迭代，并且表示经受峰值检测的F比的信号。峰值表示符号保护间隔的边界。该信息用于同步用于后续信号重建的FFT窗口。

5. 发明授权

US4066752A 1-Desamino-1-hydroxy and 1-desamino-1-epi-hydroxy-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols; 1-desamino-1-oxo-4,6-di-o-(aminoglycosyl)-1,3-diaminocyclitols, intermediates and use as antibacterial agents 失效
标题翻译： 1-脱氨基-1-羟基和1-脱氨基-1-表 - 羟基-4,6-二-O-（氨基糖基）-1,3-二氨基二醇; 1-脱氨基-1-氧代-4,6-二-O-（氨基糖基）-1,3-二氨基二醇，中间体并用作抗菌剂
公开(公告)号：US4066752A
公开(公告)日：1978-01-03
申请号：US697804
申请日：1976-06-21
申请人： Alan K. Mallams , David Huw Davies
发明人： Alan K. Mallams , David Huw Davies
IPC分类号： C07H15/22 , A61K31/71
CPC分类号： C07H15/234 , C07H15/22
摘要： This invention relates to the preparation of novel 1-desamino-1-oxo-aminoglycosides and their use as intermediates in the preparation of novel 1-desamino-1-hydroxy and 1-desamino-1-epi-hydroxyaminoglycoside antibacterial agents.
摘要翻译：本发明涉及新型1-脱氨基-1-氧代氨基糖苷类的制备及其在制备新的1-脱氨基-1-羟基和1-脱氨基-1-表 - 羟基氨基糖苷类抗菌剂中的用途。

6. 发明申请

US20100119535A1 COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS 有权
标题翻译：免疫原性抗原的组合物和方法
公开(公告)号：US20100119535A1
公开(公告)日：2010-05-13
申请号：US12447620
申请日：2007-11-01
申请人： Philip Felgner , David Huw Davies , Xiaowu Liang
发明人： Philip Felgner , David Huw Davies , Xiaowu Liang
IPC分类号： A61K39/12 , A61K39/02
CPC分类号： C12N15/1068 , A61K39/015 , A61K39/0208 , A61K39/0225 , A61K39/04 , A61K39/098 , A61K39/118 , A61K39/12 , A61K39/245 , A61K39/285 , A61K39/385 , A61K2039/60 , C07K14/005 , C12N2710/16621 , C12N2710/16622 , C12N2710/16634 , C12N2710/24122 , C12N2710/24134 , G01N33/566 , G01N33/56911 , G01N33/56916 , G01N33/56927 , G01N33/5695 , G01N33/56983 , G01N33/56994 , G01N33/6854 , G01N2333/35 , G01N2469/20 , Y02A50/401 , Y02A50/412
摘要： Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.
摘要翻译：考虑到的组合物，装置和方法包括来自选择的人类病原体的免疫显性抗原（伯克霍尔德氏菌属，布氏疏螺旋体，布鲁氏菌，衣原体衣原体，Coxiella burnetii，可用作疫苗，作为诊断标记物，以及用作治疗剂。在特别优选的方面，抗原相对于感染病原体的群体的血清具有定量和已知的相对反应性，并且具有与疾病参数的已知关联。

7. 发明授权

US4085208A Process for preparing 4,6-di-O-(aminoglycosyl)-1,3-diaminocyclitols and novel 1-epimers and 1-N-alkyl derivatives produced thereby; methods for the use of the 1-epimer derivatives as antibacterial agents and compositions useful therefor 失效
标题翻译：制备4,6-二-O-（氨基糖基）-1,3-二氨基二醇和由此产生的新的1-差向异构体和1-N-烷基衍生物的方法; 使用1-差向异构体衍生物作为抗菌剂的方法及其有用的组合物
公开(公告)号：US4085208A
公开(公告)日：1978-04-18
申请号：US697805
申请日：1976-06-21
申请人： Alan K. Mallams , David Huw Davies
发明人： Alan K. Mallams , David Huw Davies
IPC分类号： C07H15/234 , A61K31/71 , C07H15/22
CPC分类号： C07H15/234
摘要： This invention relates to the preparation of novel 1-epi-aminoglycosides, useful as antibacterial agents, and also relates to the process for the preparation of known as well as novel 1-N-substituted aminoglycoside antibacterial agents.
摘要翻译：本发明涉及可用作抗菌剂的新型1-表氨基糖苷类的制备方法，还涉及制备已知以及新的1-N-取代氨基糖苷类抗菌剂的方法。

8. 发明授权

US4009328A Aminoglycoside 66-40C, method for its manufacture, method for its use as an intermediate in the preparation of known antibiotics and novel antibacterials 失效
标题翻译：氨基糖苷66-40C，其制备方法，其用作制备已知抗生素和新型抗菌剂中的中间体的方法
公开(公告)号：US4009328A
公开(公告)日：1977-02-22
申请号：US574073
申请日：1975-05-02
申请人： Alan K. Mallams , Richard W. Tkach , David Huw Davies
发明人： Alan K. Mallams , Richard W. Tkach , David Huw Davies
IPC分类号： C07D209/48 , C07H15/236 , C07H15/22
CPC分类号： C07D209/48 , C07H15/236 , Y10S435/863
摘要： Aminoglycoside 66-40C, a minor product produced by the fermentation of Micromonospora inyoensis, is separated from said fermentation mixture, and is used as an intermediate in preparing the known antibiotic, sisomicin, as well as 6' -N-alkylsisomicins having antibacterial activity. Claimed are Aminoglycoside 66-40C as well as 6' -N-t-alkylsisomicins having a tertiary carbon bonded to the 6' -nitrogen.
摘要翻译：氨基糖苷66-40℃是通过发酵小孢子虫产生的次要产物，与所述发酵混合物分离，并用作制备已知抗生素西索米星以及具有抗菌活性的6'-N-烷基亚磺酸的中间体。要求的是氨基糖苷66-40℃以及具有与6' - 氮键合的叔碳原子的6'-N-t-烷基亚磺酸。

9. 发明授权

US3978214A Novel 4,6-di-O-(aminoglycosyl)-2-deoxystreptamine, method for its manufacture, method for its use as an antiprotozoal agent and compositions useful thereof 失效
标题翻译：新的4,6-DI-O-（氨基甲酰基）-2-脱氧谷氨酰胺，其制备方法，用作抗真菌药物的方法及其有用的组合物
公开(公告)号：US3978214A
公开(公告)日：1976-08-31
申请号：US574074
申请日：1975-05-02
申请人： Alan K. Mallams , David Huw Davies
发明人： Alan K. Mallams , David Huw Davies
IPC分类号： C07H15/236 , A61K31/71 , C07H15/22
CPC分类号： C07H15/236
摘要： The novel aminoglycoside, 0-2-amino-2,3,4-trideoxy-.alpha.-D-glycero-hex-4-enopyranosyl-(1.fwdarw.4)-garamine, is prepared by treating Aminoglycoside 66-40C with aqueous acid followed by treatment with a hydride donor reducing agent. Pharmaceutical compositions of the novel aminoglycoside and its pharmaceutically acceptable acid addition salts are described as well as their use as antiprotozoal agents.

10. 发明申请

US20140004141A1 Methods And Compositions Of Protein Antigens For The Diagnosis And Treatment Of Toxoplasma Gondii Infections And Toxoplasmosis 审中-公开
标题翻译：蛋白质抗原的方法和组成用于弓形虫感染和弓形体病的诊断和治疗
公开(公告)号：US20140004141A1
公开(公告)日：2014-01-02
申请号：US13997603
申请日：2011-12-20
申请人： David Huw Davies , Xiaowu Liang , Philip Felgner
发明人： David Huw Davies , Xiaowu Liang , Philip Felgner
IPC分类号： C07K14/45
CPC分类号： C07K14/45 , A61K39/002 , G01N33/56905
摘要： Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen T. gondii and their use in various diagnostic tests, vaccines, and therapeutic agents. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.
摘要翻译：将考虑的组合物，装置和方法绘制到来自病原体弓形虫的各种抗原及其在各种诊断测试，疫苗和治疗剂中的用途。在特别优选的方面，抗原是免疫显性的，并且相对于感染病原体的群体的血清具有定量和已知的相对反应性，和/或具有与疾病参数的已知关联。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式